New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
13:55 EDTA, A, STJ, STJ, NUVA, NUVA, JNJ, JNJ, EW, EW, COV, COV, BCR, BCR, BAX, BAX, AFFX, AFFX, SYK, SYKBofA/Merrill's healthcare analysts to hold an analyst/industry conference call
Medical Technology Analyst Hopkins, Life Science Tools Analyst de Bruin and Ketner preview 4Q12 earnings season and discuss upcoming catalysts such as Covidien's spin-off of Mallinckrodt, on an Analyst/Industry conference call to be held on January 16 at 2 pm.
News For A;AFFX;BAX;BCR;COV;EW;JNJ;NUVA;STJ;SYK From The Last 14 Days
Check below for free stories on A;AFFX;BAX;BCR;COV;EW;JNJ;NUVA;STJ;SYK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 17, 2014
09:15 EDTBAXBaxter says 'feels good' about guidance
Subscribe for More Information
08:56 EDTBAXBaxter: Guidance contemplates possible headwinds related to cyclo competition
Subscribe for More Information
07:05 EDTBAXBaxter sees Q3 EPS before special items $1.28-$1.32, consensus $1.32
The company said, "For Q3, the company expects sales growth of approximately 12%-13%, excluding the impact of foreign currency. TheQ3 earnings guidance excludes approximately 7c per diluted share of projected intangible asset amortization expense."
07:04 EDTBAXBaxter narrows FY14 adjusted EPS view to $5.10-$5.20, consensus $5.15
Subscribe for More Information
07:02 EDTBAXBaxter reports Q2 adjusted EPS $1.26, consensus $1.22
Reports Q2 revenue $4.26B, consensus $4.12B.
07:01 EDTBAXBaxter confirms FY14 outlook
Subscribe for More Information
06:41 EDTCOVCovidien downgraded to Hold from Buy at Needham
Subscribe for More Information
06:20 EDTAAgilent initiated with a Neutral at Citigroup
Target $64.
July 16, 2014
15:27 EDTBAXNotable companies reporting before tomorrow's open
Subscribe for More Information
10:36 EDTCOVTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:55 EDTJNJJohnson & Johnson pullback a buying opportunity, says Leerink
Leerink views the post-earnings pullback in shares of Johnson & Johnson as a buying opportunity. The firm expects "several" more quarters of outperformance and raised its price target for the stock to $115 from $110. It keeps an Outperform rating on J&J.
08:32 EDTSTJSt. Jude Medical sees revenue growth rate accelerating in 2H
Subscribe for More Information
08:18 EDTSTJ St. Jude Medical sees total Q3 CRM sales $660M-$690M
Sees total FY14 CRM sales $2.81B-$2.85B. Sees Q3 AF product sales $240M-$260M, FY14 AF product sales $1.3B-$1.6B. Sees Q3 cardiovascular product sales $315M-$335M, FY14 cardiovacular product sales $1.36B-$1.39B. Sees Q3 neuromodulation product sales $100M-$110M, sees FY14 neuromodulation product sales $440M-$460M. Sees $15M-$20M related to CardioMEMS product line. Says assumes R&D tax credit will be extended for 2014. Says expects to add $10M-$15M in sales related to NeuroTherm product line in 2014, sees acquisition neutral to EPS in 2014. Sees FY14 gross profit margin 71.5%-72%. Still sees FY14 SG&A as a percentage of net sales to be 33.5%-34%. Sees FY14 effective tax rate 18%-18.5%. Comments made on the Q2 earnings conference call.
07:59 EDTCOVTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical raises FY14 adjusted EPS view to $3.96-$4.01 from $3.95-$4.00
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q3 adjusted EPS 95c-97c, consensus 96c
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees FY14 adjusted EPS $3.96-$4.01, consensus $3.99
Sees FY14 revenue $5.64B-$5.76B, consensus $5.7B.
07:31 EDTSTJSt. Jude Medical reports Q2 adjusted EPS $1.02, consensus $1.00
Reports Q2 revenue $1.45B, consensus $1.44B.
07:25 EDTJNJJohnson & Johnson should be bought on pullbacks, says RBC Capital
RBC Capital believes that Johnson & Johnson reported strong Q2 results, and the company raised its estimates for the company. The firm continues to recommend buying the stock on pullbacks.
07:18 EDTNUVAScoliosis Research Society to hold annual meeting
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use